MassMutual Private Wealth & Trust FSB Has $2.51 Million Stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

MassMutual Private Wealth & Trust FSB lifted its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 140.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 6,242 shares of the pharmaceutical company’s stock after acquiring an additional 3,641 shares during the period. MassMutual Private Wealth & Trust FSB’s holdings in Vertex Pharmaceuticals were worth $2,514,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also made changes to their positions in VRTX. Willner & Heller LLC boosted its holdings in shares of Vertex Pharmaceuticals by 12.8% in the 4th quarter. Willner & Heller LLC now owns 1,211 shares of the pharmaceutical company’s stock valued at $488,000 after purchasing an additional 137 shares in the last quarter. Diversify Advisory Services LLC boosted its stake in Vertex Pharmaceuticals by 2.7% in the fourth quarter. Diversify Advisory Services LLC now owns 4,946 shares of the pharmaceutical company’s stock valued at $2,026,000 after buying an additional 131 shares in the last quarter. Diversify Wealth Management LLC grew its position in Vertex Pharmaceuticals by 160.9% in the fourth quarter. Diversify Wealth Management LLC now owns 9,773 shares of the pharmaceutical company’s stock valued at $4,002,000 after acquiring an additional 6,027 shares during the last quarter. Hall Laurie J Trustee lifted its holdings in shares of Vertex Pharmaceuticals by 8.0% in the fourth quarter. Hall Laurie J Trustee now owns 5,143 shares of the pharmaceutical company’s stock worth $2,071,000 after acquiring an additional 383 shares during the last quarter. Finally, Grove Bank & Trust boosted its stake in shares of Vertex Pharmaceuticals by 15.4% in the 4th quarter. Grove Bank & Trust now owns 473 shares of the pharmaceutical company’s stock valued at $190,000 after purchasing an additional 63 shares in the last quarter. Institutional investors and hedge funds own 90.96% of the company’s stock.

Vertex Pharmaceuticals Trading Up 1.2 %

NASDAQ:VRTX opened at $422.00 on Tuesday. The firm has a fifty day simple moving average of $440.94 and a two-hundred day simple moving average of $466.06. Vertex Pharmaceuticals Incorporated has a 12 month low of $377.85 and a 12 month high of $519.88. The stock has a market capitalization of $108.68 billion, a price-to-earnings ratio of -212.06, a PEG ratio of 2.11 and a beta of 0.40. The company has a current ratio of 2.47, a quick ratio of 2.20 and a debt-to-equity ratio of 0.01.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its earnings results on Monday, November 4th. The pharmaceutical company reported $4.38 EPS for the quarter, beating analysts’ consensus estimates of $3.61 by $0.77. The business had revenue of $2.77 billion during the quarter, compared to analyst estimates of $2.69 billion. Vertex Pharmaceuticals had a negative return on equity of 1.91% and a negative net margin of 4.52%. The firm’s revenue was up 11.6% compared to the same quarter last year. During the same period in the previous year, the company posted $3.67 EPS. Analysts expect that Vertex Pharmaceuticals Incorporated will post -1.9 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the stock. Royal Bank of Canada upped their price objective on shares of Vertex Pharmaceuticals from $437.00 to $451.00 and gave the stock a “sector perform” rating in a research report on Tuesday, November 5th. BMO Capital Markets cut their price objective on Vertex Pharmaceuticals from $566.00 to $520.00 and set an “outperform” rating on the stock in a report on Friday, December 20th. Jefferies Financial Group raised Vertex Pharmaceuticals from a “hold” rating to a “buy” rating and upped their target price for the stock from $500.00 to $550.00 in a report on Monday, December 9th. Needham & Company LLC reissued a “hold” rating on shares of Vertex Pharmaceuticals in a research note on Friday, December 20th. Finally, Morgan Stanley upped their price objective on Vertex Pharmaceuticals from $473.00 to $476.00 and gave the company an “equal weight” rating in a research note on Tuesday, November 5th. Three analysts have rated the stock with a sell rating, ten have assigned a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $490.38.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.